Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
COMMENTARY Drug Makers Downsizing Sales Forces to Increase Efficiency; Launch of Redundancy Programs to Be Continued
October 15, 2021
-
ORGANIZATION Choseido Suspended from JGA for 5 Years after Biz Suspension Order
October 15, 2021
-
ORGANIZATION EFPIA to Ponder Position on Macroeconomic Indexing with Patient Access as Top Priority, Continue Dialogue with Japan Govt
October 14, 2021
-
COMMENTARY Pharma on Alert for Possible Repeat of Minister Deal on Drug Pricing Reform
October 13, 2021
-
BUSINESS Japan Drug Makers Prepping to Launch New Organization to Solve Challenges in Digital Health
October 13, 2021
-
REGULATORY Choseido Woes Cast Clouds on Generic Inroads in Tokushima, Worst Player in Penetration
October 12, 2021
-
BUSINESS Chugai Seeks Japan Nod for Ronapreve in Prophylaxis, Asymptomatic COVID-19
October 12, 2021
-
BUSINESS Ivermectin COVID-19 Trial Needed Because Evidence Is Lacking, Kowa Says as It Aims for PIII Wrap-Up in November
October 11, 2021
-
REGULATORY MHLW Orders Large-Scale Carcinogen Risk Inspections, Covering Almost All Drugs
October 11, 2021
-
REGULATORY Choseido Hit by Biz Suspension of Up to 31 Days over Manufacturing Flaws
October 11, 2021
-
REGULATORY Japan Clinches Deal for 120 Million Extra Pfizer Vaccine Doses
October 8, 2021
-
BUSINESS Licensing Izcargo to Takeda First Step to Expanded Application of JCR’s BBB-Penetrating Technology: Chairman
October 8, 2021
-
ORGANIZATION JMA Exec Chides Pharma for Requesting Price Measure to Ensure Stable Supplies, Says Compliance System Should Come First
October 7, 2021
-
BUSINESS Takeda Suspends PII Trials of Narcolepsy Drug Hopeful on Safety Concerns
October 7, 2021
-
BUSINESS Oncolys Aims to Bring Nucleocapsid Inhibitor into Clinic Next Year for COVID-19 Treatment
October 6, 2021
-
REGULATORY Transparency and Predictability Up for Discussion towards 2022 Drug Pricing Reform: New Minister
October 6, 2021
-
REGULATORY New Health Minister Goto Vows to Protect Secure Healthcare System in FY2022 Reform
October 5, 2021
-
REGULATORY No Factor to Impede Reinstatement of HPV Vaccine Recommendation: Panels
October 4, 2021
-
ORGANIZATION FPMAJ to Define Shipment Situation in Preparation for Supply Information Centralization
October 1, 2021
-
BUSINESS Sumitomo Dainippon, Otsuka Ink Global Collaboration for 4 Neuropsychiatric Drugs
October 1, 2021
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…